These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22018293)

  • 1. New targets to treat the structural remodeling of the myocardium.
    González A; Ravassa S; Beaumont J; López B; Díez J
    J Am Coll Cardiol; 2011 Oct; 58(18):1833-43. PubMed ID: 22018293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U; Wollert KC; Drexler H
    Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of myocardial matrix remodeling by adipokines in obesity-related heart failure.
    Schram K; Sweeney G
    Trends Cardiovasc Med; 2008 Aug; 18(6):199-205. PubMed ID: 19185809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory cytokines and postmyocardial infarction remodeling.
    Nian M; Lee P; Khaper N; Liu P
    Circ Res; 2004 Jun; 94(12):1543-53. PubMed ID: 15217919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted deletion of nuclear factor kappaB p50 enhances cardiac remodeling and dysfunction following myocardial infarction.
    Timmers L; van Keulen JK; Hoefer IE; Meijs MF; van Middelaar B; den Ouden K; van Echteld CJ; Pasterkamp G; de Kleijn DP
    Circ Res; 2009 Mar; 104(5):699-706. PubMed ID: 19168865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological therapeutics based on molecular mechanisms].
    Akazawa H; Komuro I
    Nihon Rinsho; 2006 May; 64(5):897-903. PubMed ID: 16689371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of concepts: cardiac extracellular matrix remodeling after myocardial infarction.
    Cleutjens JP; Creemers EE
    J Card Fail; 2002 Dec; 8(6 Suppl):S344-8. PubMed ID: 12555143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular evidence of reverse cardiac remodeling induced by cardiac resynchronization therapy.
    Orrego CM; Nasir N; Oliveira GH; Flores-Arredondo JH; Cordero-Reyes AM; Loebe M; Youker KA; Torre-Amione G
    Congest Heart Fail; 2011; 17(3):140-6. PubMed ID: 21609388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload.
    Janicki JS; Brower GL; Gardner JD; Forman MF; Stewart JA; Murray DB; Chancey AL
    Cardiovasc Res; 2006 Feb; 69(3):657-65. PubMed ID: 16376324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The structural examination of myocardial samples from patients with end-stage heart failure supported by ventricular assist devices using electron microscopy and amino acid analysis reveals low degree of reverse remodeling.
    Milting H; Jacob M; Kassner A; Heimann P; Mannherz HG; Becker G; Meyer HE; Böthig D; Arusoglu L; Morshuis M; Körfer R; El Banayosy A
    J Heart Lung Transplant; 2004 Apr; 23(4):396-404. PubMed ID: 15063398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
    Yang YJ; Zhang X; Zhu WL; Huang Y
    Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of apoptosis in remodeling after myocardial infarction.
    Takemura G; Fujiwara H
    Pharmacol Ther; 2004 Oct; 104(1):1-16. PubMed ID: 15500905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased production of CXCL16 in experimental and clinical heart failure: a possible role in extracellular matrix remodeling.
    Dahl CP; Husberg C; Gullestad L; Waehre A; Damås JK; Vinge LE; Finsen AV; Ueland T; Florholmen G; Aakhus S; Halvorsen B; Aukrust P; Oie E; Yndestad A; Christensen G
    Circ Heart Fail; 2009 Nov; 2(6):624-32. PubMed ID: 19919988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left ventricular eccentric remodeling and matrix loss are mediated by bradykinin and precede cardiomyocyte elongation in rats with volume overload.
    Ryan TD; Rothstein EC; Aban I; Tallaj JA; Husain A; Lucchesi PA; Dell'Italia LJ
    J Am Coll Cardiol; 2007 Feb; 49(7):811-21. PubMed ID: 17306712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel approaches to retard ventricular remodeling in heart failure.
    Spinale FG
    Eur J Heart Fail; 1999 Mar; 1(1):17-23. PubMed ID: 10937974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HMGB1: the missing link between diabetes mellitus and heart failure.
    Volz HC; Seidel C; Laohachewin D; Kaya Z; Müller OJ; Pleger ST; Lasitschka F; Bianchi ME; Remppis A; Bierhaus A; Katus HA; Andrassy M
    Basic Res Cardiol; 2010 Nov; 105(6):805-20. PubMed ID: 20703492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat.
    See F; Thomas W; Way K; Tzanidis A; Kompa A; Lewis D; Itescu S; Krum H
    J Am Coll Cardiol; 2004 Oct; 44(8):1679-89. PubMed ID: 15489104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Embracing diversity in remodeling: a step in therapeutic decision making in heart failure?
    Chandrashekhar Y
    J Am Coll Cardiol; 2007 Feb; 49(7):822-5. PubMed ID: 17306713
    [No Abstract]   [Full Text] [Related]  

  • 19. TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'.
    Vanhoutte D; Heymans S
    J Mol Cell Cardiol; 2010 Mar; 48(3):445-53. PubMed ID: 19799912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of intravenous immunoglobulin in the treatment of chronic heart failure.
    Aukrust P; Yndestad A; Ueland T; Damås JK; Frøland SS; Gullestad L
    Int J Cardiol; 2006 Sep; 112(1):40-5. PubMed ID: 16893578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.